Hansa Biopharma AB (publ) (OTCMKTS:HNSBF) Sees Significant Increase in Short Interest

Hansa Biopharma AB (publ) (OTCMKTS:HNSBF) was the recipient of a significant increase in short interest during the month of February. As of February 15th, there was short interest totalling 641,700 shares, an increase of 95.8% from the January 31st total of 327,700 shares. Based on an average daily volume of 0 shares, the days-to-cover ratio is presently ∞ days.

Hansa Biopharma AB (publ) Price Performance

Shares of HNSBF stock remained flat at $3.00 during trading hours on Friday. Hansa Biopharma AB has a fifty-two week low of $2.83 and a fifty-two week high of $3.65. The stock has a 50-day moving average price of $2.98 and a two-hundred day moving average price of $3.09.

Hansa Biopharma AB (publ) Company Profile

Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Europe and the United States. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test.